Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | Q9HBH1 | 1/20 | 0.41 | |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245289 | 0.91 | SSTR3 (0.53) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL22010347 | 0.89 | SSTR3 (0.51) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL19340304 | 0.87 | SSTR3 (0.51) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL20133503 | 0.81 | MMP3 (0.47) | SSTR3CALCRLLTA4HMMP3MMP1 | |
| SCHEMBL24472056 | 0.80 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL24766216 | 0.80 | GNPAT (0.60) | SSTR3CALCRLECE1MMP3MMP1 | |
| SCHEMBL23682519 | 0.80 | GNPAT (0.48) | SSTR3CALCRLECE1MMP3MMP1 | |
| SCHEMBL24476084 | 0.80 | GNPAT (0.48) | SSTR3CALCRLECE1MMP3MMP1 | |
| SCHEMBL18811838 | 0.80 | GNPAT (0.48) | SSTR3CALCRLECE1MMP3MMP1 | |
| SCHEMBL14821040 | 0.79 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | SSTR3 622/4885CALCRL 3449/4885LTA4H 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.